1. Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome

   • Yee-Jen Wu
   • Chien-Chih Wu
   • Chi-Chuan Wang

   OriginalPaper 31 March 2024 Pages: 537 - 546

   

2. Antithrombotic strategies for preventing graft failure in coronary artery bypass graft

   • Maria Sara Mauro
   • Simone Finocchiaro
   • Davide Capodanno

   ReviewPaper Open access 16 March 2024 Pages: 547 - 557

   

3. Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease

   • Zekang Ye
   • Qin Wang
   • Chunjian Li

   OriginalPaper Open access 23 February 2024 Pages: 558 - 565

   

4. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory

   • Paul A. Gurbel
   • Kevin Bliden
   • Udaya S. Tantry

   OriginalPaper 13 March 2024 Pages: 566 - 575

   

5. Impact of rise and fall phases of shear on platelet activation and aggregation using microfluidics

   • Xuemei Gao
   • Tiancong Zhang
   • Yuan Li

   OriginalPaper 31 March 2024 Pages: 576 - 586

   

6. A systematic review of therapeutic enoxaparin dosing in obesity

   • Maya R. Chilbert
   • Kimberly Zammit
   • Ashley E. Woodruff

   ReviewPaper 25 February 2024 Pages: 587 - 597

   

7. Management of direct oral anticoagulant drug interactions in hospitalized patients

   • Mohsen H. Al Zaria
   • Leo F. Buckley
   • John Fanikos

   OriginalPaper 30 March 2024 Pages: 598 - 602

   

8. Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity

   • Jeffrey D. Sperry
   • Aletha Loeb
   • Jennifer A. Szwak

   OriginalPaper 26 February 2024 Pages: 603 - 612

   

9. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa

   • Julius Chacha Mwita
   • Joel Msafiri Francis
   • Karen Cohen

   OriginalPaper Open access 13 March 2024 Pages: 613 - 621

   

10. One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke

    • Yasutaka Murakami
    • Kenichi Todo
    • Hideki Mochizuki

    OriginalPaper Open access 31 March 2024 Pages: 622 - 629

    

11. The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review

    • L. Al-Tourah
    • S. Mithoowani
    • Rick Ikesaka

    OriginalPaper 01 March 2024 Pages: 630 - 637

    

12. Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database

    • Bang Truong
    • Lori Hornsby
    • Jingjing Qian

    OriginalPaper Open access 20 March 2024 Pages: 638 - 649

    

13. Superficial vein thrombosis and its relationship with malignancies: a prospective observational study

    • Alejandro Díez-Vidal
    • Javier Gómez López
    • Yale Tung-Chen

    OriginalPaper 16 March 2024 Pages: 650 - 657

    

14. A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants

    • Benjamin Wee
    • Jeffrey Lai
    • Brandon Lui

    OriginalPaper 23 February 2024 Pages: 658 - 667

    

15. Prediction of mortality in acute pulmonary embolism in cancer-associated thrombosis (MAUPE-C): derivation and validation of a multivariable model

    • Mario Aramberri
    • Jesús González-Olmedo
    • Carmen Diaz-Pedroche

    OriginalPaper 14 March 2024 Pages: 668 - 676

    

16. Management of DOAC-related bleeding in cancer patients: a single center-case series

    • Sophia Lee
    • Jeremy A. Ross
    • Cristhiam M. Rojas Hernandez

    OriginalPaper 31 March 2024 Pages: 677 - 682

17. Discrimination of the acute pulmonary embolism subtypes based on the novel MAPH score

    • Onur Akhan
    • Mustafa Boz
    • Mehmet Kis

    OriginalPaper 28 February 2024 Pages: 683 - 690

    

18. Is a minimum duration of 5 days of unfractionated heparin infusion necessary before transition to oral anticoagulation in cerebral venous thrombosis? a retrospective chart review

    • Ariel N. Carrion
    • Teresa A. Allison
    • Sophie Samuel

    OriginalPaper 28 February 2024 Pages: 691 - 698

    

19. Therapeutic implication of MicroRNA-320a antagonist in attenuating blood clots formed during venous thrombosis

    • Swati Srivastava
    • Iti Garg
    • Rajeev Varshney

    OriginalPaper 23 February 2024 Pages: 699 - 709

    

20. Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry

    • Omri Cohen
    • Gili Kenet
    • and the RIETE investigators

    OriginalPaper 16 March 2024 Pages: 710 - 720

21. Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity

    • Erica Okazaki
    • Bárbara Gomes Barion
    • Fernanda Andrade Orsi

    OriginalPaper 25 March 2024 Pages: 721 - 729

    

22. COVID-19 vaccination affects short-term anti-coagulation levels in warfarin treatment

    • Li-Hua Liu
    • Yang-Zhao Zhou
    • Sheng-Lan Tan

    OriginalPaper 25 March 2024 Pages: 730 - 738

    

23. Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

    • Richard J Buka
    • David J Sutton
    • Phillip LR Nicolson

    Letter to the Editor 15 February 2024 Pages: 739 - 741